Generics Urged to Get Involved in Fight Against Counterfeiting
While counterfeiting is believed mainly to affect brand drugmakers, the practice, as well as various anticounterfeiting measures, has implications for generic companies, an industry expert says.
In the U.S., political discussion of the pharmaceutical industry is focused on drug safety and the cost of healthcare, but in Europe a current hot-button issue is counterfeit medicines, Greg Perry, director general of the European Generic medicines Association (EGA), said at a conference this week.
7 December 2007